Lacosamide Fresenius Kabi

Lacosamide, the active ingredient in Lacosamide Fresenius Kabi, is an anti‑epileptic presented as an intravenous solution for intravenous use. It is used as adjunctive therapy for partial‑onset seizures in adults and children with focal epilepsy.

GNH USA supplies Lacosamide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant indicated for the treatment of seizure disorders.

Partial‑onset seizures: Reduces seizure frequency when added to existing anti‑seizure regimens. Focal epilepsy: Used as adjunctive therapy to improve overall seizure control. Refractory focal seizures: Provides an additional option for patients not adequately controlled by other agents.

Common Side Effects: - Dizziness: Transient sensation of light‑headedness. - Nausea: Mild to moderate gastrointestinal upset. - Headache: Usually mild and resolves with continued therapy. - Fatigue: Generalized tiredness, often improving over time. - Blurred vision: Temporary visual disturbances. - Diplopia: Double vision that may lessen with dose adjustment.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmias. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal ideation: New or worsening thoughts of self‑harm. - Hypersensitivity: Anaphylactic reactions or severe rash. - Hepatic dysfunction: Elevated liver enzymes or hepatitis.

Before initiating therapy, clinicians should consider several safety factors.

Pregnancy: Category C; weigh potential benefits against fetal risks. Renal impairment: Dose may need adjustment; monitor renal function. Hepatic impairment: Use cautiously; monitor liver enzymes. Cardiac conduction: Baseline ECG recommended; monitor PR interval. Concomitant CNS depressants: Increased sedation risk; adjust dosing as needed. Store at ambient temperature below 25°C: Keep in original container, protect from moisture and light.

Lacosamide may interact with several medications; monitoring is essential.

Major Interactions (Avoid): - Strong CYP2C19 inhibitors (e.g., fluconazole): May raise lacosamide plasma levels. - Drugs that prolong PR interval (e.g., class IA antiarrhythmics): Heightened risk of cardiac conduction delay. - Other sodium‑channel blockers (e.g., carbamazepine): Increased risk of CNS depression.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs (e.g., valproate, phenytoin): May require dose adjustments. - Alcohol or CNS depressants: Potential additive sedation. - Renally cleared agents (e.g., aminoglycosides): Monitor renal function and drug levels.